Literature DB >> 11948419

Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity.

Dimpy Koul1, Samar A Jasser, Yiling Lu, Michael A Davies, Ruijun Shen, Yuexi Shi, Gordon B Mills, W K Alfred Yung.   

Abstract

The tumor suppressor gene, MMAC/PTEN, has phosphatase, C2, and PDZ-binding domains as well as potential sites of regulation by phosphorylation, including tyrosine phosphorylation, which may contribute to its ability to modulate cell growth and viability. Several obvious and significant motifs were found in MMAC/PTEN, including most notably, a catalytic domain of tyrosine phosphatase (IHCxxGxxRS/T) and several potential tyrosine phosphorylation sites. To examine the functional significance of tyrosine phosphorylation of MMAC/PTEN, retroviral constructs were generated with mutations at two putative tyrosine phosphorylation sites (Y240A/Y240F and Y315A/Y315F). Stable expression of wild-type MMAC/PTEN in U251 human glioma cells (which do not normally produce a functional MMAC/PTEN gene product) resulted in a significant reduction of tumor growth in nude mice, decreased growth rate, saturation density, and colony formation in vitro, as well as dephosphorylation of D3-phosphorylated phosphatidylinositols (PtdIns) in vitro. Mutation of Y240 or Y315 to either alanine or phenylalanine abrogated the ability of MMAC/PTEN to alter growth rate, saturation density, and colony formation in vitro. The ability of MMAC/PTEN to limit tumor growth in nude mice was markedly decreased but not abrogated by mutation of Y240 or Y315 to alanine. Thus, Y240 and Y315 are required for MMAC/PTEN to decrease tumor growth in vitro and in vivo. In contrast to wild-type MMAC/PTEN, mutant MMAC/PTEN containing Y240A or Y315A was unable to dephosphorylate D3-phosphorylated PtdIns in vitro. Thus, Y240A and Y315A are involved in the ability of MMAC/PTEN to dephosphorylate PtdIns and regulate tumor cell growth in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948419     DOI: 10.1038/sj.onc.1205296

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

Authors:  Dimpy Koul; Jun Fu; Ruijun Shen; Tiffany A LaFortune; Shuzhen Wang; Ningyi Tiao; Yong-Wan Kim; Juinn-Lin Liu; Deepti Ramnarian; Ying Yuan; Carlos Garcia-Echevrria; Sauveur-Michel Maira; W K Alfred Yung
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

Review 3.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

4.  PTEN enhances TNF-induced apoptosis through modulation of nuclear factor-kappaB signaling pathway in human glioma cells.

Authors:  Dimpy Koul; Yasunari Takada; Ruijun Shen; Bharat B Aggarwal; W K Alfred Yung
Journal:  Biochem Biophys Res Commun       Date:  2006-09-25       Impact factor: 3.575

Review 5.  Molecular mechanisms of peritoneal dissemination in gastric cancer.

Authors:  Mitsuro Kanda; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2.

Authors:  Ming Lin; Xuyu Zhang; Bingjie Jia; Su Guan
Journal:  J Neurooncol       Date:  2017-11-08       Impact factor: 4.130

7.  Identification of nucleolus-localized PTEN and its function in regulating ribosome biogenesis.

Authors:  Pingdong Li; Danni Wang; Haiyang Li; Zhenkun Yu; Xiaohong Chen; Jugao Fang
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

Review 8.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 9.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

10.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.